About us

Canada's Michael Smith Genome Sciences Centre (GSC) at BC Cancer is an international leader in genomics, proteomics, and bioinformatics for precision medicine. By developing and deploying genome sequencing, computational and analytical technology, we are creating novel strategies to prevent and diagnose cancers and other diseases, uncovering new therapeutic targets, and helping the world realize the social and economic benefits of genome science

Learn more about how the GSC is Bringing Genomics to Life.

Why work at the GSC

As the first genome centre to be established within a cancer clinic, our story began by thinking outside of the box. From being the first in the world to sequence the SARS coronavirus during the 2003 global outbreak to publishing the first study demonstrating the use of whole-genome sequencing to influence personalized cancer treatment planning in 2010, our passion for pushing scientific frontiers continues to this day.

Our technology platforms enable the transformative science being done at the GSC, but it is our world-class team of scientists and innovators that make it happen. By joining the GSC you will become part of a diverse and dedicated group of biologists, bioinformaticians, computer scientists, computational biologists, biochemists, engineers, and clinicians. We look for people who share our core values—science, timeliness, and respect—to join us in our mission to provide genomics, bioinformatics, and proteomics technology and expertise for the benefit of human health and society.

We believe that diversity and inclusivity are essential for the advancement of human knowledge and science. We welcome all applicants and provide all employees with equal opportunity for advancement, regardless of race, colour, ancestry, place of origin, political belief, religion, marital status, family status, physical or mental disability, sex, sexual orientation, gender identity or expression, age, conviction of a criminal or summary conviction offence unrelated to their employment.

All qualified candidates are encouraged to apply; however, Canadian citizens and permanent residents will be given priority.

*Due to COVID-19 restrictions, the position would require working remotely on part-time temporary basis as well as in the lab.  This restriction would be re-evaluated upon re-contracting*

Role Summary:

The Evgin Laboratory at Canada’s Michael Smith Genome Science (GSC) at BC Cancer is looking for a qualified candidate to aid in the development of novel oncolytic viruses and cellular immunotherapies. Projects include preclinical studies utilizing in vivo and in vitro models of cancer and infection and seek to develop combinatorial therapeutic approaches. The individual will aid in setting up a new lab space and thus organizational skills and attention to detail are paramount.

The successful candidate will have a PhD or equivalent degree and at least five years of relevant experience.

Knowledge of and research experience with standard methods and approaches in microbiology, immunology, cell biology, molecular biology, virology, genomics and mouse models are assets; and familiarity with the fields of cancer immunology and immunotherapy are highly desirable.

The applicant should also demonstrate the ability to work independently, supervise trainees and technical staff, and conceive, initiate, prioritize, organize and manage multiple concurrent projects.  Excellent verbal and written communication skills are a necessity as well as the ability to work in a team environment. 

This position will begin ASAP.  This is a one-year term appointment subject to annual renewal. 

Salary will be commensurate with qualifications and experience.

Please submit a cover letter, curriculum vitae, and the names of three referees willing to provide letters of reference to bcgscjobs@bcgsc.ca. The cover letter should include a brief description of your previous research experience and long-term career goals, plus supervisory and administrative service. 

Please not that this position will remain open until filled.

Back to top